{'fraction_non_alphanumeric': 0.01406926406926407, 'fraction_numerical': 0.01406926406926407, 'mean_word_length': 5.335616438356165, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
SULBACTAM/AMPICILLIN IN CHILDREN WITH BACTERIAL PNEUMONIA

Sulbactam is a betalactamase inhibitor which in combination with Ampicillin expands the spectrum of the latter to include Ampicillin resistant germs. To document the efficacy and safety of Sulbactam/Ampicillin a clinical study was performed in 25 children suffering from pneumonia. The dosage of Sulbactam/Ampicillin was 50 mg Sulbactam/100 mg Ampicillin per kg per day administered in three divided doses. Clinical cure was achieved in 22 children and failure of treatment was observed in 3 children. Side effects occured in 2 patients in form of transient exanthema which did not necessitate termination of treatment. Slight and transient elevation of transaminases was observed in 4 children and transient eosinophilia occured in 2 patients. The results confirmed that Sulbactam/Ampicillin is an effective and well-tolareted treatment in children with pneumonia.